Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dutogliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 18/20 | 1.00 |
| ▸ | FAP | Q12884 | 19/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.72 |
| ▸ | PREP | P48147 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dutogliptin SCHEMBL5502671 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| Dutogliptin SCHEMBL1236486 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| Dutogliptin SCHEMBL5526847 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| Dutogliptin SCHEMBL8030287 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| Dutogliptin SCHEMBL8160917 | 1.00 | FAP (1.00) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL13713813 | 0.94 | FAP (0.88) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL7901017 | 0.94 | FAP (0.88) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL13997343 | 0.94 | FAP (0.88) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL7898224 | 0.94 | FAP (0.88) | FAPDPP4DPP8DPP9DPP7 | |
| SCHEMBL7896597 | 0.92 | FAP (0.85) | FAPDPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1527 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636284-B2 | Compositions for use in the prevention and/or treatment of intellectual disability and neurodegenerative diseases in a subject with down syndrome | Universita' Degli Studi Di Roma “La Sapienza” (IT) | 2026-05-26 | — | — | US | claimed |
| EP-4735023-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Piton Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | Elite Pharmaceutical Solution Inc. (US) | 2026-04-14 | — | — | US | claimed |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2025-10-09 | — | — | US | claimed |
| EP-4596044-A2 | COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS | Mankind Pharma Ltd. (IN) | 2025-08-06 | — | — | EP | claimed |
| US-20250241992-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | GILA THERAPEUTICS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-20250144097-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES WITH DIABETES | ARIBIO CO LTD (KR) | 2025-05-08 | — | — | US | claimed |
| EP-4337192-B1 | COMPOSITIONS FOR USE IN THE PREVENTION AND/ OR TREATMENT OF INTELLECTUAL DISABILITY AND NEURODEGENERATIVE DISEASES IN A SUBJECT WITH DOWN SYNDROME | UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) | 2025-04-30 | — | — | EP | claimed |
| EP-4514359-B1 | NOVEL DUTOGLIPTIN FORMULATIONS AND THEIR PREPARATION | RECARDIO INC (US) | 2025-04-16 | — | — | EP | claimed |
| WO-2025057088-A1 | RNA COMPOSITIONS FOR DELIVERY OF INCRETIN AGENTS | BioNTech SE (DE) | 2025-03-20 | — | — | WO | claimed |
| JP-2011529945-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-20110263493-A1 | Treatment for diabetes in patients inappropriate for metformin therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | claimed |
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | claimed |
| US-20110190322-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | US | claimed |
| EP-2326326-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-06-01 | — | — | EP | claimed |
| EP-2323650-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | claimed |
| WO-2011005929-A1 | PIPERIDINE DERIVATIVE AND ITS USE FOR THE TREATMENT OF DIABETS AND OBESITY | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | claimed |
| US-7674913-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2010-03-09 | — | — | US | claimed |
| WO-2010018217-A2 | ORGANIC COMPOUNDS FOR WOUND HEALING | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | WO | claimed |
| WO-2010015664-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 82/4885DPP8 5/4885 |
| US-12636284-B2 | Compositions for use in the prevention and/or treatment of intellectual disability and neurodegenerative diseases in a subject with down syndrome | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 47/4885DPP8 5/4885 |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | GLP1R, DPP4, SLC5A2 | DPP4 2/4885FAP 774/4885DPP8 11/4885 |
| US-20110263493-A1 | Treatment for diabetes in patients inappropriate for metformin therapy | DPP4, DPP3, DPP7 | DPP4 1/4885FAP 82/4885DPP8 5/4885 |
| US-20110190322-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 12/4885DPP8 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.